Box–Behnken design-assisted optimization of RP-HPLC method for the estimation of evogliptin tartrate by analytical quality by design

[1] Tan X(2016)Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type-2 diabetes Expert Opin Pharmacother 17 1285-1293

[2] Hu J(2021)Evogliptin a new drug of DPP-4 inhibitor: an overview World J Pharm Res 5 1921-1929

[3] Thakkar K(2015)Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 38 140-149

[4] Patel K(2018)Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates renal fibrosis caused by unilateral ureteral obstruction in mice Diabetes Meta J 43 271-278

[5] Inzucchi SE(2009)Statement by an American Association of Clinical Endocrinologists American college of Endocrinology consensus penal on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract 15 540-559

[6] Bergenstal RM(2021)Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation Exp Mol Med 52 1744-1753

[7] Buse JB(2015)Beneficial effects of Evogliptin, a novel dipeptidyl peptidase 4 inhibitor, on adiposity with increased Ppargc1a in white adipose tissue in obese mice PLoS ONE 10 e0144064-464

[8] Diamant M(2018)Absorption, metabolism, and excretion of [14C] evogliptin tartrate in male rats and dogs J Toxicol Environ Health 81 453-192

[9] Ferrannini E(2021)A stability indicating RP-HPLC method validation for simultaneous estimation of metformin HCl and canagliflozin in pharmaceutical dosage form J Pharm Res 33 180-767

[10] Nauck M(2021)A stability indicating RP-HPLC method validation for simultaneous estimation of metformin HCl, dapagliflozin and saxagliptin in pharmaceutical dosage form J Pharm Res 33 754-1923

[1] Tan X(2016)Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type-2 diabetes Expert Opin Pharmacother 17 1285-1293

[2] Hu J(2021)Evogliptin a new drug of DPP-4 inhibitor: an overview World J Pharm Res 5 1921-1929

[3] Thakkar K(2015)Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 38 140-149

[4] Patel K(2018)Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates renal fibrosis caused by unilateral ureteral obstruction in mice Diabetes Meta J 43 271-278

[5] Inzucchi SE(2009)Statement by an American Association of Clinical Endocrinologists American college of Endocrinology consensus penal on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract 15 540-559

[6] Bergenstal RM(2021)Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation Exp Mol Med 52 1744-1753

[7] Buse JB(2015)Beneficial effects of Evogliptin, a novel dipeptidyl peptidase 4 inhibitor, on adiposity with increased Ppargc1a in white adipose tissue in obese mice PLoS ONE 10 e0144064-464

[8] Diamant M(2018)Absorption, metabolism, and excretion of [14C] evogliptin tartrate in male rats and dogs J Toxicol Environ Health 81 453-192

[9] Ferrannini E(2021)A stability indicating RP-HPLC method validation for simultaneous estimation of metformin HCl and canagliflozin in pharmaceutical dosage form J Pharm Res 33 180-767

[10] Nauck M(2021)A stability indicating RP-HPLC method validation for simultaneous estimation of metformin HCl, dapagliflozin and saxagliptin in pharmaceutical dosage form J Pharm Res 33 754-1923